Home
  Abstracts
  ASCO Daily News
  About the Meeting
  Attendee Information
  Meeting Program
  Presenter and Faculty Resources
  Exhibitor Information
  Public & Patient Information
  Past Annual Meetings

Abstracts > Abstract Changes or Withdrawals

Abstract Changes or Withdrawals

Changes
First Authors may request corrections to rectify errors (e.g., typos, misspellings) within abstract submissions. Requests must be submitted by Friday, April 15.

  • Updates to original data will not be permitted, as changes are permissible only for the correction of errors.
  • Include the abstract ID, title, and an explanation of the changes to be made to the original text.  

  Requests for changes must be sent by the First Author to abstracts@asco.org.

Please call 571-483-1400 or 1-800-516-5850 with any questions.

Withdrawals
If a First Author chooses to withdraw his or her abstract for any reason, a request must be submitted by Friday, April 15.

  • Any abstract withdrawal request received after this date will be considered on a case-by-case basis and cannot be assured removal from the 2011 ASCO Annual Meeting Proceedings.
  • The First Author of a Late-breaking Abstract may request that the abstract be withdrawn if the updated abstract is deemed acceptable for online publication only by the Committee at the time of review.

  Requests for withdrawals may be sent by the First Author to abstracts@asco.org.

Requests may also be made by phone at 571-483-1400 or 1-800-516-5850.

Abstract Announcements and Exceptions
According to ASCO's Abstract Policy, abstracts submitted to the Annual Meeting are confidential from the time of submission until the specified embargo lift date and time when the data becomes publicly available. Under extenuating circumstances, ASCO may grant a formal exception to its Abstract Policy. Abstract Policy Exceptions require advance approval by ASCO before the information is made public.

ASCO has granted formal Policy Exceptions for the following abstracts to allow limited information to be made publicly available in advance of the Annual Meeting due to Securities and Exchange Commission (SEC) requirements:

Abstract LBA7512
An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC)

Abstract LBA5
Phase 3 randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) vs DTIC alone as first line treatment in patients with unresectable stage III or IV melanoma

Abstract LBA5007
OCEANS: A randomized, double-blinded, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)

Abstract 6500
Results of COMFORT- I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) vs placebo (PB) for patients with myelofibrosis (MF)

Abstract 7503
Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European erlotinib versus chemotherapy (EURTAC) phase III randomized trial

Abstract LBA4
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma

Abstract Status Changes
Occasionally, an abstract will be withdrawn, removed or demoted in program placement after it has been published as part of the program. The following abstracts have either been withdrawn, removed or demoted:

Abstract LBA7512
An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC)  
WebsiteFeedback